Drug reaction with eosinophilia and systemic symptoms (DRESS): An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study

British Journal of Dermatology

Volumn 169, Issue 5, 2013, Pages 1071-1080

  Kardaun, S H ^a   Sekula, P ^b   Valeyrie Allanore, L ^c   Liss, Y ^b   Chu, C Y ^d   Creamer, D ^e   Sidoroff, A ^f   Naldi, L ^g   Mockenhaupt, M ^b   Roujeau, J C ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HENRI MONDOR HOSPITAL   (France)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMOXICILLIN; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DEXAMETHASONE; FLUINDIONE; LAMOTRIGINE; MINOCYCLINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; SALAZOSULFAPYRIDINE; SULFADIAZINE; SULFONAMIDE; SULTAMICILLIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BLISTER; CLINICAL ARTICLE; COMORBIDITY; DISEASE REGISTRY; DRESS SYNDROME; DRUG ERUPTION; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DYSPHAGIA; ECZEMA; EOSINOPHILIA; EPILEPSY; ERYTHRODERMA; EYE DISEASE; FACE EDEMA; FEMALE; FEVER; GENITAL SYSTEM DISEASE; GOUT; HEART DISEASE; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; IMMUNOCOMPROMISED PATIENT; KIDNEY DISEASE; LEUKOCYTOSIS; LICHENOID; LIP DISEASE; LIVER DISEASE; LUNG DISEASE; LYMPHADENOPATHY; LYMPHOCYTE; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MACULOPAPULAR RASH; MALE; MEDICATION COMPLIANCE; MONOCYTOSIS; MOOD DISORDER; MOUTH DISEASE; MOUTH LESION; MUCOSAL DRYNESS; MUSCLE DISEASE; NEUTROPHILIA; OBSERVATIONAL STUDY; ORGAN INJURY; OUTCOME ASSESSMENT; PAIN; PANCREAS DISEASE; PHARMACOEPIDEMIOLOGY; PHOTOGRAPHY; POLYPHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PURPURA; PUSTULE; RASH; SCORING SYSTEM; SEIZURE; SEX RATIO; SIDE EFFECT; SKIN PAIN; SPLEEN DISEASE; SYSTEMIC THERAPY; THROAT DISEASE; THROMBOCYTOPENIA; THROMBOCYTOSIS; UBIQUITOUS EXANTHEMA; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADULT; AGED; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY SYNDROME; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES;

EID: 84887102194     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12501     Document Type: Article

References (46)

1. Bocquet H, Bagot M, Roujeau JC,. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250-7.
2. Chaiken BH, Goldberg BI, Segal JP,. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950; 242: 897-8.
3. Iwatsuki K, Tsugiki M, Tagami H, Yamada M,. Infectious mononucleosis-like manifestations. An adverse reaction to sulfasalazine. Arch Dermatol 1984; 120: 964-5.
4. Vittorio CC, Muglia JJ,. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285-90.
5. Shiohara T, Inaoka M, Kano Y,. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006; 55: 1-8.
6. Kardaun SH, Scheffer E, Vermeer BJ,. Drug-induced pseudolymphomatous skin reactions. Br J Dermatol 1988; 118: 545-52.
7. Tohyama M, Hashimoto K, Yasukawa M, et al,. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007; 157: 934-40.
8. Kano Y, Shiohara T,. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am 2009; 29: 481-501.
9. Tennis P, Stern RS,. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997; 49: 542-6.
10. Shear NH, Spielberg SP,. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82: 1826-32.
11. Roujeau JC, Stern RS,. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
12. Callot V, Roujeau JC, Bagot M, et al,. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol 1996; 132: 1315-21.
13. Agrawal S, Agarwalla A,. Dapsone hypersensitivity syndrome: a clinico-epidemiological review. J Dermatol 2005; 32: 883-9.
14. Tas S, Simonart T,. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology 2003; 206: 353-6.
15. Chiou CC, Yang LC, Hung SI, et al,. Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol 2008; 22: 1044-9.
16. Chen YC, Chiu HC, Chu CY,. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010; 146: 1373-9.
17. Roujeau JC,. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209: 123-9.
18. Cacoub P, Musette P, Descamps V, et al,. The DRESS syndrome: a literature review. Am J Med 2011; 124: 588-97.
19. Descamps V, Valance A, Edlinger C, et al,. Association of human herpes virus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301-4.
20. Kano Y, Inaoka M, Shiohara T,. Association between anticonvulsant syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004; 140: 183-8.
21. Kano Y, Hiraharas K, Sakuma K, Shiohara T,. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006; 155: 301-6.
22. Hung SH, Chung WH, Liou LB, et al,. HLAB* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-9.
23. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al,. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156: 609-11.
24. Peyrière H, Dereure O, Breton H, et al,. Network of the French Pharmacovigilance Centers. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155: 422-8.
25. Ben Mrad M, Leclerc-Mercier S, Blanche P, et al,. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine 2009; 88: 131-40.
26. Um SJ, Lee SK, Kim YH, et al,. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. Investig Allergol Clin Immunol 2010; 20: 556-62.
27. Jeung YJ, Lee JY, Oh MJ, et al,. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and Stevens-Johnson syndrome. Allergy Asthma Immunol Res 2010; 2: 123-6.
28. Pereira de Silva N, Piquioni P, Kochen S, Saidon P,. Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antiepileptic drugs. Eur J Clin Pharmacol 2011; 67: 463-70.
29. Wongkitisophon P, Chanprapaph K, Rattanakaemakorn P, Vachiramon V,. Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms. Acta Derm Venereol 2011; 92: 200-5.
30. Bastuji-Garin S, Rzany B, Stern RS, et al,. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
31. Sidoroff A, Halevy S, Bavinck JN, et al,. Acute generalized exanthematous pustulosis (AGEP)-a clinical reaction pattern. J Cutan Pathol 2001; 28: 113-19.
32. Mockenhaupt M, Viboud C, Dunant A, et al,. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44.
33. Sidoroff A, Dunant A, Viboud C, et al,. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157: 989-96.
34. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K,. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol 2007; 156: 1083-4.
35. Tefferi A,. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc 2005; 80: 75-83. Review.
36. Brito-Babapulle F,. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003; 121: 203-23.
37. Suzuki Y, Inagi R, Aono T, et al,. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1998; 134: 1108-12.
38. Picard D, Janela B, Descamps V, et al,. Drug Reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010; 2: 46ra62.
39. Sassolas B, Haddad C, Mockenhaupt M, et al,. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010; 88: 60-8.
40. Mockenhaupt M,. Epidemiology and causes of severe cutaneous adverse reactions to drugs. In: Drug Hypersensitivity (, Pichler WJ, ed). Basel: Karger, 2007; 18-31.
41. Eshki M, Allanore L, Musette P, et al,. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009; 145: 67-72.
42. Halevy S, Ghislain PD, Mockenhaupt M, et al,. Allopurinol is the most common cause of Stevens Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
43. Teraki Y, Shibuya M, Izaki S,. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations. Clin Exp Dermatol 2010; 35: 723-8.
44. Kardaun SH, Kuiper H, Fidler V, Jonkman MF,. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis. J Cutan Pathol 2010; 37: 1220-9.
45. Halevy S, Kardaun SH, Davidovici B, et al,. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol 2010; 163: 1245-52.
46. Roujeau JC, Kelly JP, Naldi L, et al,. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7.